Why the Creso Pharma (ASX:CPH) share price fell 9% before freezing

Creso Pharma shares came to a halt this afternoon, here's what is happening…

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Creso Pharma Ltd (ASX: CPH) share price came under pressure this afternoon. This followed breaking news published by The Australian Financial Review involving the cannabis and psychedelics company's non-executive chair, Adam Blumenthal.

Shares in the small-cap company tumbled 9% to 12.3 cents apiece before being placed into a trading halt. The frozen share price will remain in place until Creso can respond to the ASX's price query.

However, the intriguing news today relates to the office raid of Mr Blumenthal.

A dollar sign embedded in ice, indicating a share price freeze or trading halt

Image source: Getty Images

Creso Pharma share price falls amid ASIC investigation at EverBlu

Investors weren't playing around this afternoon after they got word of what was going on in Sydney today. It appears shareholders were quite nervous about the news that Creso Pharma's non-exec chair, Blumenthal, had his office raided by the Australian Federal Police (AFP) today.

To be clear, the office raided was not that of Creso Pharma. Rather, it was Blumenthal's boutique corporate advisory company, EverBlu Capital.

According to reports, officers were adorning gloves and flicking through files to assist the Australian Securities and Exchange Commission (ASIC) with an investigation. Neither the AFP nor ASIC have shed any further light on exactly what the investigation is in relation to.

The EverBlue Capital team was involved in advising Creso Pharma on its bonus options issue in October. My colleague, Zach, covered this at the time, outlining how the financial instrument could be used to raise capital if exercised.

Talk about timing

As fate would have it, the precarious situation has come to light mere days after Creso Pharma handed down its trading update for Q4 FY21. Overall, the update was reasonably positive for the company, pushing The Creso Pharma share price higher.

Furthermore, the quarter saw the company achieve strong revenue growth in its Swiss operations. However, the market's sentiment might now be tainted by the latest developments involving Adam Blumenthal.

The Creso Pharma share price will remain halted until an announcement is provided, or until the commencement of trade on Thursday, 18 November 2021.

Motley Fool contributor Mitchell Lawler has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Scientists in white coats look disappointed.
Healthcare Shares

$5,000 invested in CSL shares 12 months ago is now worth…

Are the biotech company's shares worth holding onto?

Read more »

Happy healthcare workers in a lab.
Healthcare Shares

Clarity Pharmaceuticals shares are up 12% today. Here's what's driving the move

Today's announcement moves Clarity a step closer towards commercialisation.

Read more »

A medical specialist holds a red heart connected via technology and artificial intelligence.
Healthcare Shares

Which ASX biotech's shares are rocketing higher on big US news?

This company has more than doubled in value over the past three months.

Read more »

A man with a wry smile on his face is shown close up behind ascending piles of coins as he places another coin on top of the tallest stack representing rising dividends
Healthcare Shares

Here's the dividend forecast out to 2030 for CSL shares

Can healthy dividends continue from CSL?

Read more »

A woman researcher holds a finger up in happiness as if making the 'number one' sign with a graphic of technological data and an orb emanating from her finger while fellow researchers work in the background.
Healthcare Shares

Forget CSL shares, this ASX healthcare stock could double in value

Brokers see significantly more upside ahead for Pro Medicus.

Read more »

Lab worker puts hands in the air and dances around.
Healthcare Shares

CSL shares look primed to take off — Here's why

Business remains robust and brokers see ASX stock soaring up to 100%.

Read more »

A group of people in a corporate setting do a collective high five.
Healthcare Shares

ASX 300 healthcare stock outperforming today on 'strategic' leadership news

The ASX healthcare stock announced the outcome of its CEO recruitment drive this morning.

Read more »

Cropped shot of a young female scientist working on her computer in the laboratory.
Healthcare Shares

Could Telix shares be a millionaire-maker stock?

Telix looks a compelling growth story, with brokers eyeing more than 150% upside.

Read more »